Ocugen, Inc. reported earnings results for the second quarter and six months ended June 30, 2025. For the second quarter, the company reported revenue was USD 1.37 million compared to USD 1.14 million a year ago. Net loss was USD 14.74 million compared to USD 15.28 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.06 a year ago.
For the six months, revenue was USD 2.85 million compared to USD 2.16 million a year ago. Net loss was USD 30.09 million compared to USD 27.2 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.11 a year ago.
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
